Totus Medicines employs uses AI/ML and innovative DNA-encoded covalent library tech to discover small molecule medicines.
Totus Medicines has raised $66.0M in total funding. The most recent round was Series B. The last funding was announced in December 2023.
Totus Medicines's investors include DCVC Bio, Social Impact Capital, Northpond Ventures, Regents of The University of Minnesota, Camford Capital.
Totus Medicines is headquartered in Cambridge, United States.
Totus Medicines employs uses AI/ML and innovative DNA-encoded covalent library tech to discover small molecule medicines.
Totus Medicines is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Totus Medicines — Funding & Investors." VCBacked, December 15, 2023, https://www.vcbacked.co/company/totus-medicines. Accessed July 19, 2026.
VCBacked. (2023). Totus Medicines — Funding & Investors. Retrieved July 19, 2026, from https://www.vcbacked.co/company/totus-medicines
{{cite web |title=Totus Medicines — Funding & Investors |url=https://www.vcbacked.co/company/totus-medicines |website=VCBacked |access-date=July 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated